Home' Australian Pharmacist : Australian Pharmacist February 2016 Contents Australian Pharmacist February 2016 I ©Pharmaceutical Society of Australia Ltd.
Make the dream of becoming a doctor a reality, earn
your MD at Oceania University of Medicine.
Attractive fee structure for our Graduate Entry Program.
Over 150 students currently enrolled and over 50
graduates in Australia, New Zealand, Samoa and USA.
Home-based Pre-Clinical Study under top international
medical school scholars, using world leading Pre-Clinical,
24/7 online delivery techniques.
Clinical Rotations can be performed locally, Interstate or
Receive personalised attention from an Academic Advisor.
OUM Graduates are eligible to sit the AMC exam or NZREX.
OCEANIA UNIVERSITY OF MEDICINE
INTERNATIONALLY ACCREDITED For information visit www.oceaniamed.org or 1300 665 343
Applications now open for courses starting in January & July - No age restrictions
BPharm to MD
inno ative approach
is allowing me
to realise my
Pharmacist from Cairns
Class of 2017
DDS o ering full $1 discount
Discount Drug Stores (DDS) is passing on the full $1 discount on all eligible
prescriptions following recent changes to the Pharmaceutical Benefits
Scheme (PBS), and has priced its over-the-counter medications to offset
In early December Chemist Warehouse
announced it would implement the full
DDS is also providing free healthcare
plans to 'assist customers in achieving
the best savings for their circumstance.'
The PBS changes, which came into effect
1 January, allow pharmacies to choose
whether to apply a further $1 discount
to government subsidised medications.
According to a consumer flyer released
by the Pharmacy Guild of Australia
if a concessional patient takes the
$1 discount they will need an additional
11 prescriptions during the year to reach
the safety net threshold and access free
'Concessional patients who take the
$1 discount must still spend the same
total amount during the year to access
free medicines on the Safety Net. If you
take the $1 discount your access to free
medicines will start later in the year and
the length of time you are eligible for
free medicines will be reduced,' the Guild
DDS Executive General Manager
Doug Kuskopf-Dallas said the group
was offering the discount to benefit
consumers, but encouraged the public
to consider their own circumstances,
as the discount could actually
'Concessional customers who take
up the offer may take longer to reach
their safety net threshold, which could
delay their access to free medicine
and may affect their compliance to
their medication as prescribed by their
doctor,' Mr Kuskopf-Dallas said.
Under the Safety Net, once a concessional
customer reaches the threshold their
remaining prescriptions are given free of
charge for the remainder of the year.
Pharmacist and National Pharmaceuticals
Manager for DDS, Stephenie Shea, said
concession cardholders who receive
the $1 discount will need to purchase
11 extra prescriptions per year to reach
their safety net.
'This means both a longer wait until
they can receive free medications, and
the length of time they are eligible for
free medicines will be reduced, since the
safety net re-sets each year,' Ms Shea said.
'That's why Discount Drug Stores is
taking a more tailored approach and
encouraging customers to speak with
their pharmacist to discuss their options,'
Mr Kuskopf-Dallas said.
'It's about empowering our customers so
they can make informed decisions about
what's best for their situation.'
Ms Shea also warned of other negative
impacts the PBS changes may have on
Takeda sells respiratory
portfolio to AZ
Takeda Pharmaceutical Company Limited
has entered into a definitive agreement
to sell its respiratory portfolio to
In 2014 Takeda defined four therapeutic
areas of focus: gastroenterology,
oncology, central nervous system, and
cardiovascular and metabolic. By selling
its respiratory portfolio Takeda will be able
to to work on these therapeutic areas.
Takeda's Chief Executive Officer
Christophe Weber said: 'Patients are
Takeda's primary focus and we are
committed to working closely with
AstraZeneca to ensure a smooth
transition. 'AstraZeneca has extensive
experience in respiratory care and will be
able to prioritise getting these important
medicines to the patients that need them.'
Under the terms of the agreement,
AstraZeneca will acquire the respiratory
business including the products Daxas
(roflumilast), Alvesco and Omnaris
(ciclesonide). The acquisition will also
include regional and local products,
as well as several pre-clinical assets.
A number of Takeda employees will
transfer to AstraZeneca upon completion
of the divestiture.
Links Archive Australian Pharmacist January 2016 Australian Pharmacist March 2016 Navigation Previous Page Next Page